Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Refractory neuro-Behçet treated by tocilizumab: a case report.

Urbaniak P, Hasler P, Kretzschmar S.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S73-5. Epub 2012 Sep 27.

PMID:
23020826
2.

Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab.

Studer U, Ruehe B, Waldegg G, Vajtai I, Escher R, Aeberli D.

Rheumatol Int. 2012 May;32(5):1431-5. doi: 10.1007/s00296-011-1915-x. Epub 2011 Mar 29.

PMID:
21445544
3.

Neurological complications of Behçet's syndrome.

Kidd D.

Curr Neurol Neurosci Rep. 2012 Dec;12(6):675-9. doi: 10.1007/s11910-012-0316-1. Review.

PMID:
23007835
4.

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.

Mod Rheumatol. 2012 Apr;22(2):298-302. doi: 10.1007/s10165-011-0497-5. Epub 2011 Jul 12.

PMID:
21748365
5.

Successful treatment of long-standing neuro-Behçet's disease with infliximab.

Sarwar H, McGrath H Jr, Espinoza LR.

J Rheumatol. 2005 Jan;32(1):181-3.

PMID:
15630746
6.

[Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].

Kadowaki S, Matsuda N, Moriya A, Ebitani M, Yoshihara A, Nakamura K, Mochizuki H, Ugawa Y.

Rinsho Shinkeigaku. 2011 Apr;51(4):261-6. Japanese.

PMID:
21595295
7.

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.

Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y.

Rheumatology (Oxford). 2009 Aug;48(8):1012-3. doi: 10.1093/rheumatology/kep126. Epub 2009 May 22. No abstract available.

PMID:
19465589
8.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
9.

Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.

Kanemaru H, Makino T, Jinnin M, Yonemitsu A, Makino K, Ihn H.

J Dermatol. 2013 Aug;40(8):632-4. doi: 10.1111/1346-8138.12203. Epub 2013 Jun 3.

PMID:
23724912
10.

Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.

Leccese P, D'Angelo S, Angela P, Coniglio G, Olivieri I.

Clin Exp Rheumatol. 2010 Jul-Aug;28(4 Suppl 60):S102. Epub 2010 Sep 24. No abstract available.

PMID:
20868587
11.

The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.

Morris DS, Gavin MP, Sturrock RD.

Adv Exp Med Biol. 2003;528:557-9. No abstract available.

PMID:
12918763
12.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.

PMID:
24359625
13.

Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, Arima K, Kamachi M, Tamai M, Huang M, Nakamura H, Nishiura Y, Origuchi T, Ida H, Eguchi K.

Ann Rheum Dis. 2007 Jan;66(1):136-7. No abstract available.

14.

Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.

Olivieri I, D' Angelo S, Padula A, Leccese P, Mennillo GA.

Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S112. No abstract available.

PMID:
19796550
15.

Effect of infliximab in progressive neuro-Behçet's syndrome.

Kikuchi H, Aramaki K, Hirohata S.

J Neurol Sci. 2008 Sep 15;272(1-2):99-105. doi: 10.1016/j.jns.2008.05.002. Epub 2008 Jun 11.

PMID:
18550081
16.

Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.

Belzunegui J, López L, Paniagua I, Intxausti JJ, Maíz O.

Clin Exp Rheumatol. 2008 Jul-Aug;26(4 Suppl 50):S133-4. No abstract available.

PMID:
19026138
17.

TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.

Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S129-37. Epub 2015 Oct 20. Review.

PMID:
26486925
18.

Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF.

Rheumatol Int. 2011 Aug;31(8):1097-9. doi: 10.1007/s00296-009-1276-x. Epub 2009 Dec 11.

PMID:
20012049
19.
20.

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.

Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M.

Arthritis Res Ther. 2012 May 1;14(3):R99. doi: 10.1186/ar3824.

Supplemental Content

Support Center